Last reviewed · How we verify
SARSCoV2 Convalescent Plasma
At a glance
| Generic name | SARSCoV2 Convalescent Plasma |
|---|---|
| Sponsor | AdventHealth |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Testing Convalescent Plasma vs Best Supportive Care (PHASE1)
- Intermediate IND Severe Illness COVID-19 CP (PHASE1)
- Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma (NA)
- Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients (PHASE2)
- Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection (NA)
- Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation (PHASE2)
- Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 (PHASE3)
- Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARSCoV2 Convalescent Plasma CI brief — competitive landscape report
- SARSCoV2 Convalescent Plasma updates RSS · CI watch RSS
- AdventHealth portfolio CI